Sugi Predict

Sugi Predict / Compounds / SCHEMBL25757796

SCHEMBL25757796

SCHEMBL25757796

COc1c(NC(=O)OC(C)(C)C)ccn2ncc(C3CC3)c12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DGAT1 O75907 2/20 0.43
▸ JAK2 O60674 2/20 0.35
▸ JAK1 P23458 1/20 0.35
▸ TYK2 P29597 1/20 0.35
▸ JAK3 P52333 1/20 0.35
▸ TP53 P04637 2/20 0.35
▸ IDO1 P14902 2/20 0.34
▸ MAPKAPK2 P49137 1/20 0.34
▸ GSK3B P49841 1/20 0.34
▸ DYRK1A Q13627 1/20 0.34
▸ PDE4B Q07343 1/20 0.34
▸ NPBWR1 P48145 2/20 0.33
▸ MCHR1 Q99705 2/20 0.33
▸ CHRM1 P11229 1/20 0.33
▸ METAP1 P53582 1/20 0.33
▸ POLB P06746 1/20 0.33
▸ MAPT P10636 1/20 0.33
▸ NTRK1 P04629 1/20 0.33
▸ PIK3CD O00329 1/20 0.33
▸ ABL1 P00519 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30895110 0.85 DGAT1 (0.35) DGAT1IDO1GSK3BDYRK1AMETAP1
SCHEMBL30895038 0.85 ITGA4 (0.36) DGAT1IDO1GSK3BDYRK1APDE4B
SCHEMBL27199361 0.85 NPBWR1 (0.38) NPBWR1MCHR1POLBMAPT
SCHEMBL25757793 0.84 NR1I2 (0.34) DGAT1IDO1GSK3BDYRK1AMETAP1
SCHEMBL25757107 0.83 ATR (0.42) DGAT1IDO1POLBMAPT
SCHEMBL25757841 0.83 ATR (0.35) DGAT1TP53IDO1GSK3BDYRK1A
SCHEMBL30895044 0.83 PCSK9 (0.36) DGAT1IDO1MAPKAPK2GSK3BDYRK1A
SCHEMBL25757792 0.83 ATR (0.35) DGAT1IDO1GSK3BDYRK1AMAPT
SCHEMBL25757842 0.82 IDO1 (0.37) DGAT1IDO1GSK3BDYRK1AMETAP1
SCHEMBL25757532 0.82 PCSK9 (0.36) DGAT1IDO1GSK3BDYRK1AMETAP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250115597-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO LTD (CN) 2025-04-10 — — US disclosed
US-12129250-B2 TYK2 inhibitors and compositions and methods thereof LYNK PHARMACEUTICALS CO. LTD. (CN) 2024-10-29 — — US disclosed
CN-118401516-A TYK2 inhibitors, compositions and methods thereof 凌科药业(杭州)有限公司 2024-07-26 — — CN disclosed
US-20240124448-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO. LTD. (CN) 2024-04-18 — — US disclosed
WO-2023109954-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO. LTD. (CN) 2023-06-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240124448-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF TYK2, JAK2, JAK1 DGAT1 3938/4885JAK2 2/4885JAK1 3/4885
US-20250115597-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF TYK2, JAK2, JAK1 DGAT1 3938/4885JAK2 2/4885JAK1 3/4885
US-12129250-B2 TYK2 inhibitors and compositions and methods thereof TYK2, JAK2, JAK1 DGAT1 3938/4885JAK2 2/4885JAK1 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.